Arrowhead Pharmaceuticals (ARWR) is back in focus after fresh regulatory approvals for REDEMPLO in China and Canada, along ...

Arrowhead Pharmaceuticals recently announced that Health Canada issued a Notice of Compliance for REDEMPLO (plozasiran) as an ...

As of Wednesday, January 07, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 7.85%, which has investors questioning if this is right time to buy.

The use of poison on arrows marked a revolution in human hunting technology—new evidence suggests it happened tens of ...

Shares of Arrowhead Pharmaceuticals rose after the company reported positive interim data from two Phase 1/2 trials for obesity treatments. The stock was up 17%, at $74.61, late Tuesday morning and ...

This limited-series pairs a completely new, handcrafted body with the proven technical foundation and sublime driving ...

In terms of liquidity and interest, the mean open interest for Arrowhead Pharma options trades today is 878.14 with a total volume of 5,476.00.

As more patients seek lasting, tech-forward solutions to tooth loss, the practice adapts with expanded implant services ...

From first purchase to long-term preservation — what every collector should know We don’t own these machines — we ...

Arrowhead Pharmaceuticals said Tuesday that its gene-silencing drug candidate nearly doubled four-month weight loss ...

IJT ETF overview: small-cap growth portfolio with 17% earnings growth, 20x P/E and lower tech exposure than IVW. See why it’s ...

With the one-year anniversary of the Palisades and Eaton fires, builders expect a flood of permit applications in 2026.